Peter Nicholson has worked in the biopharmaceutical and medical device industries for over 30 years. Since 2007 he has served as Director, Corporate Development for Galderma S.A., a dermatology-focused joint venture between Nestlé and L’Oréal, where he is responsible for strategy and external growth initiatives. Previously he was Vice President, Corporate Development for Mentor Corporation where he successfully divested the company’s urology business and refocused its strategy on the aesthetic business, which ultimately led to its acquisition by Johnson & Johnson. He served in a similar role at Inamed where he refined the company’s strategy and successfully executed a number of business development agreements and revitalized the company’s international presence prior to its acquisition by Allergan. Nicholson worked at Amgen for six years in roles of increasing responsibility in product development and product licensing and was responsible for starting and managing the company’s venture program. He worked at two small medical device companies, Telios and Advanced Tissues Sciences where he was a member of the teams focused developing products addressing unmet needs for wound healing and burns. He pursued research on monoclonal antibodies at Triton Biosciences and Allergenetics where he was focused on identifying and isolating new growth factors.
Mr. Nicholson received a master’s degree in business administration from the University of California at Los Angeles where he won the Knapp venture capital competition. He was a founder and Chief